Iovance Biotherapeutics reported early pilot trial results for lifileucel in aggressive soft tissue sarcomas. The company plans to start a registrational trial and seek expedited FDA approval based on ...

Kaposi sarcoma-associated herpesvirus testing is not routinely performed on donors or reci ...

Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik® (tazemetostat) in all ...

The University of Iowa Health Care Holden Comprehensive Cancer Center has started treating its second patient — the second in the state — with a cellular therapy to fight synovial sarcoma, a rare and ...

Rates infection related cancer have increased among solid organ transplant recipients, CDC reports a five-fold rise in Kaposi sarcoma virus transmission.

Results presented here showed negative pressure wound therapy is a safe adjunct for soft tissue sarcoma treated with ...

Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...

PARIS, FRANCE, 09 March 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today that it is voluntarily withdrawing Tazverik (tazemetostat) in all indications from all Ipsen markets. Ipsen's decision ...

After surviving Ewing Sarcoma, 14-year-old Jude Baker used his Make-A-Wish not for a trip, but to help people experiencing ...

Ipsen has pulled Tazverik from all markets after a trial found risks of secondary blood cancers, affecting patients with follicular lymphoma and epithelioid sarcoma.

The study demonstrated a favourable safety profile for DT-9081.